08:34 AM EST - BriaCell Therapeutics Corp. : Announced that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic breast cancer. FDA has approved the study design, the primary and secondary endpoints, and patient population in BriaCell’s upcoming pivotal registration clinical study. The study will include advanced metastatic breast cancer patients who have exhausted all other treatment options. BriaCell Therapeutics Corp.
shares N.BCTX are trading up 37 cents at $6.51.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BCTX&qmodStoryID=7731169555259569
